Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 7

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 7
---
 of Medical Affairs). 12.1. (i) to approve a new maximum aggregate amount of CHF [•](cash based compensation including all applicable social security contributions) for the fixed compensation of the Board of Directors, (ii) to approve the grant of equity or equity linked instruments with maximum aggregate amount of CHF [•](equity or equity linked instruments including all applicable social security contributions) for the compensation of Board of Directors and (iii) to approve the participation in the purchase of a run -offinsurance policy for the members of the Board of Directors, to be effective at the time of the Merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the current term of office until the next Ordinary Shareholders Meeting. 12.2. (i) to approve the new maximum aggregate amount of CHF [•](cash compensation including all applicable social security contributions) for the fixed compensation of the Company’s executive officers, (ii) to approve the new maximum aggregate amount of CHF [•](cash compensation including all applicable social security contributions) for the variable compensation of the Company’s executive officers, (iii) to approve the grant of equity or equity linked instruments with maximum aggregate amount of CHF [•](equity or equity linked instruments including all applicable social security contributions) for the Company’s executive officers, and (iv) to approve the participation in the purchase of a run -offinsurance policy for the Company’s executive officers, to be effective at the time of the Merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the financial year 2025.

13.To approve the CVR Agreement on an advisory basis. 14.To approve the conversion of outstanding options and restricted stock units (“RSUs”), issued by Kadimastem into equivalent securities with identical rights in the Company at the time of the completion of the transactions contemplated by the Merger Agreement. We know of no other matters to be submitted at the NLS Meeting other than as specified herein. If any other business is properly brought before the NLS Meeting, the persons named as proxies may vote in respect thereof in accordance with their best judgment. After careful consideration, the NLS Board has determined that the Merger is fair to and in the best interests of NLS and its shareholders, has approved the Merger Agreement, the Merger, the issuance of the NLS Common Shares to Kadimastem’s shareholders pursuant to the terms of